We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01224106
First Posted: October 19, 2010
Last Update Posted: November 7, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Hoffmann-La Roche
October 14, 2010
October 19, 2010
November 7, 2017
November 30, 2010
July 22, 2020   (Final data collection date for primary outcome measure)
Mean Change From Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) Total Score at Week 104 [ Time Frame: Baseline, Week 104 ]
  • To evaluate the effect on the change in the Clinical Dementia Rating scale Sum of Boxes (CDR-SOB), a global measure of cognition and functional ability [ Time Frame: 2 years ]
  • Substudy: Change in brain amyloid over time assessed with Positron Emission Tomography [ Time Frame: 2 years ]
Complete list of historical versions of study NCT01224106 on ClinicalTrials.gov Archive Site
  • Mean Change From Baseline in Alzheimer Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog-11) Scores at Week 104 [ Time Frame: Baseline, Week 104 ]
  • Time to Onset of Dementia [ Time Frame: Every 6 months to up to 3 years (1096 days) ]
  • Mean Change From Baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Composite Score at Week 104 [ Time Frame: Baseline, Week 104 ]
  • Mean Change from Baseline in Free and Cued Selective Reminding Test (FCSRT) Score at Week 104 [ Time Frame: Baseline, Week 104 ]
  • Mean Change From Baseline in Functional Activities Questionnaire (FAQ) Score at Week 104 [ Time Frame: Baseline, Week 104 ]
  • Mean Change From Baseline in CDR-Global Score at Week 104 [ Time Frame: Baseline, Week 104 ]
  • Mean Change from Baseline in Neuropsychiatric Inventory (NPI) Questionnaire Score at Week 104 [ Time Frame: Baseline, Week 104 ]
  • Percent Change from Baseline in Cerebrospinal Fluid Biomarkers (Phosphorylated-tau [p-tau], Amyloid Beta 1-42 [Abeta 1-42], Total tau [t-tau]) at Week 104 [ Time Frame: Baseline, Week 104 ]
  • Percent Change from Baseline in Hippocampal Volume at Week 104 [ Time Frame: Baseline, Week 104 ]
  • Percent Change From Baseline in Cortical Composite Sustained Uptake Volume Ratio (SUVr) in Different Brain Regions at Week 156 [ Time Frame: Baseline, Week 156 ]
  • Gantenerumab Plasma Concentration at Different Time Points [ Time Frame: Prior to injections at Weeks 1, 8, 20, 44, 53, 68, 100, 101 ]
  • Mean Change From Baseline in Mini Mental State Exam (MMSE) Score at Week 104 [ Time Frame: Baseline, Week 104 ]
  • Effect on cognition assessed with Alzheimer Disease Assessment Scale-Cognition [ Time Frame: 2 years ]
  • Effect on functioning assessed with Functional Activities Questionnaire [ Time Frame: 2 years ]
  • Safety (nature and incidence of adverse events) [ Time Frame: 2 years ]
  • Pharmacokinetics: gantenerumab levels [ Time Frame: 2 years ]
Not Provided
Not Provided
 
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease and Up to Three Years of an Open-Label Extension With Active Study Treatment
This multi-center, randomized, double-blind, placebo-controlled parallel-group study will evaluate the effect of gantenerumab (RO4909832) on cognition and functioning and the safety and pharmacokinetics in participants with prodromal Alzheimer's Disease. Participants will be randomized to receive subcutaneous (SC) injections of either gantenerumab or placebo. Participants who consent to be part of the sub study will undergo positron emission tomography (PET) scanning to assess brain amyloid. The anticipated time on study treatment is 104 weeks, with an option for an additional 2 years of treatment.
Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Alzheimer's Disease
  • Drug: Gantenerumab
    Participants will receive gantenerumab 105 or 225 mg SC injection q4w.
  • Drug: Placebo
    Participants will receive placebo SC injection q4w.
  • Experimental: Gantenerumab 105 mg (Parts 1 and 2)
    Participants with Alzheimer's disease will receive gantenerumab 105 milligrams (mg) by SC injection every 4 weeks (q4w) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who complete the Week 104 visit will be given an option to continue the treatment received during Part 1 for 2 additional years in Part 2.
    Intervention: Drug: Gantenerumab
  • Experimental: Gantenerumab 225 mg (Parts 1 and 2)
    Participants with Alzheimer's disease will receive gantenerumab 225 mg by SC injection q4w for 104 weeks or approximately 2 years during Part 1 of the study. Participants who complete the Week 104 visit will be given an option to continue the treatment received during Part 1 for 2 additional years in Part 2.
    Intervention: Drug: Gantenerumab
  • Placebo Comparator: Placebo (Parts 1 and 2)
    Participants with Alzheimer's disease will receive placebo SC injection q4w for 104 weeks or approximately 2 years during Part 1 of the study. Participants who complete the Week 104 visit will be given an option to continue the treatment received during Part 1 for 2 additional years in Part 2.
    Intervention: Drug: Placebo
Delrieu J, Ousset PJ, Vellas B. Gantenerumab for the treatment of Alzheimer's disease. Expert Opin Biol Ther. 2012 Aug;12(8):1077-86. doi: 10.1517/14712598.2012.688022. Epub 2012 May 15. Review.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
799
July 22, 2020
July 22, 2020   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adult participants, 50-85 years of age
  • Participants with prodromal Alzheimer's disease who are not receiving memantine or cholinesterase inhibitors
  • Has a study partner who in the investigator's judgement has frequent and sufficient contact with the participant as to be able to provide accurate information as to the participant's cognitive and functional abilities, who agrees to provide information at clinic visits which require partner input for scale completion
  • Has had sufficient education or work experience to exclude mental retardation
  • Study partner has noticed a recent gradual decrease in participant's memory (over the last 12 months), which the participant may or may not be aware of
  • Screening Mini Mental State Exam (MMSE) score of 24 or above

Additional inclusion criteria for sub study:

  • Able and willing to travel to PET imaging center and complete the planned scanning sessions
  • Past and planned exposure to ionizing radiation not exceeding safe and permissible levels

Exclusion Criteria:

  • Other prior or current neurologic or medical disorder which may currently or during the course of the study impair cognition or psychiatric functioning
  • A history of stroke
  • A documented history of transient ischemic attack within the last 12 months
  • History of schizophrenia, schizoaffective or bipolar disorder
  • Currently meets criteria for major depression
  • Within the last 2 years, unstable or clinical significant cardiovascular disease (myocardial infarction, angina pectoris)

Additional exclusion criteria for sub study:

  • Inclusion in a research and/or medical protocol involving PET ligands or other radioactive agents within 12 months
  • Present or planned participation in a research and/or medical protocol involving PET ligands or radioactive agents other than study WN25203
  • Have planned or are planning to have exposure to ionizing radiation that in combination with the planned administration with study amyloid PET ligand would result in a cumulative exposure that exceeds local recommended exposure limits
Sexes Eligible for Study: All
50 Years to 85 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Argentina,   Australia,   Belgium,   Brazil,   Canada,   Chile,   Czechia,   Denmark,   Finland,   France,   Germany,   Israel,   Italy,   Korea, Republic of,   Mexico,   Netherlands,   Poland,   Portugal,   Russian Federation,   Spain,   Sweden,   Switzerland,   Turkey,   United Kingdom,   United States
Czech Republic
 
NCT01224106
WN25203
2010-019895-66 ( EudraCT Number )
Not Provided
Not Provided
Not Provided
Hoffmann-La Roche
Hoffmann-La Roche
Not Provided
Study Director: Clinical Trials Hoffmann-La Roche
Hoffmann-La Roche
November 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP